US5767274A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prenyl transferase inhibitors
Assignee: Ipsen Pharma SAS
•
Filing: 1996-06-28
•
Granted: 1998-06-16
•
Expires: 2016-06-28
Abstract
Abstract A family of compounds capable of inhibiting the activity of prenyl transferases. The compounds are covered by either of the two following formulas ##STR1## Each of the R groups is defined in the disclosure.
Inventors
- 👤 Sun H. Kim
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 09:30
CPC Classifications
C; C07; C07D; C07D513/00; C07D513/02; C07D513/04; A; A61; A61K; A61K31/00; A61K31/33; A61P; A61P13/00; A61P13/08; A61P35/00; A61P43/00; A61P9/00; A61P9/10; C07C; C07C323/00; C07C323/50; C07C323/51; C07C323/60; C07D217/00; C07D217/22; C07D217/26; C07D241/00; C07D241/02; C07D241/04; C07D285/00; C07D285/36; C07D285/38; C07D339/00; C07D417/00; C07D417/02; C07D417/06; C07D417/14; C07D513/12; C07D513/14; C07K; C07K5/00; C07K5/04; C07K5/06; C07K5/06008; C07K5/06017; C07K5/0606; C07K5/08; C07K5/0802; C07K5/0804; C07K5/081; A61K38/00
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
187 words
A compound of the formula I or formula II ##STR4## wherein R 1 is N(R 10 )(R 11 ); R 2 is thio lower alkyl; each of R 3 and R 5 , independently, is CH 2 or C(O); R 4 is thio lower alkyl, wherein the free thio groups of R 2 and R 4 form a disulfide bond; R 6 is a residue of a natural or synthetic α-amino acid R 7 is a residue of a natural or synthetic α-amino acid; R 8 is OH or lower alkoxy, or, together with R 7 , forms homoserinelactone; each of R 9 , R 10 , R 11 , independently, is H or lower alkyl; R 12 is a substituted or unsubstituted moiety selected from cycloalkyl, cycloalkyl lower alkyl, aryl, aryl lower alkyl, heterocycle, and heterocycle lower alkyl, wherein the substituent is lower alkyl, aryl, halo, lower alkoxy, or C(O)--R 7 --R 8 ; R 13 is lower alkyl, aryl, or aryl lower alkyl; R 18 is H or, together with R 9 , forms --CH 2 CH 2 --; or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
187 words
A compound of the formula I or formula II ##STR4## wherein R 1 is N(R 10 )(R 11 ); R 2 is thio lower alkyl; each of R 3 and R 5 , independently, is CH 2 or C(O); R 4 is thio lower alkyl, wherein the free thio groups of R 2 and R 4 form a disulfide bond; R 6 is a residue of a natural or synthetic α-amino acid R 7 is a residue of a natural or synthetic α-amino acid; R 8 is OH or lower alkoxy, or, together with R 7 , forms homoserinelactone; each of R 9 , R 10 , R 11 , independently, is H or lower alkyl; R 12 is a substituted or unsubstituted moiety selected from cycloalkyl, cycloalkyl lower alkyl, aryl, aryl lower alkyl, heterocycle, and heterocycle lower alkyl, wherein the substituent is lower alkyl, aryl, halo, lower alkoxy, or C(O)--R 7 --R 8 ; R 13 is lower alkyl, aryl, or aryl lower alkyl; R 18 is H or, together with R 9 , forms --CH 2 CH 2 --; or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
18 words
A compound of claim 1, wherein said compound is of formula I; or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
18 words
A compound of claim 1, wherein said compound is of formula II; or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
143 words
A compound of claim 2, wherein R 6 is --N(R 14 )CH(R 15 )C(O)-- where R 14 is H or lower alkyl, and R 15 is a substituted or unsubstituted moiety selected from lower alkyl, aryl, aryl lower alkyl, heterocycle, and heterocycle lower alkyl, in which said substituent is lower alkyl, halo, or lower alkoxy, or R 15 , together with N(R 14 )C attached thereto, form a heterocycle; R 7 is --N(R 16 )CH(R 17 )C(O)-- where R 16 is H or lower alkyl; and R 17 is (CH 2 ) m S(O) n CH 3 where m is 1-6 and n is 0-2, or is a substituted or unsubstituted moiety selected from lower alkyl and thio lower alkyl, where said substituent is C(O)N(R 10 )(R 11 ); and R 8 is OH or lower alkoxy; or a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
47 words
A compound of claim 4, wherein R 2 is CH 2 SH; and R 4 is C(CH 3 ) 2 SH or CH 2 SH; in which the free thio groups of R 2 and R 4 form a disulfide bond; or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
42 words
A compound of claim 5, wherein R 15 , together with N(R 14 )C attached hereto, form a heterocycle; R 16 is H; and R 17 is (CH 2 ) 2 S(O) n CH 3 ; or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
37 words
A compound of claim 6, wherein R 1 is NH 2 ; R 3 is CH 2 ; R 5 is C(O); and R 8 is OH or OCH 3 ; or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
47 words
A compound of claim 3, wherein R 2 is CH 2 SH; and R 4 is C(CH 3 ) 2 SH or CH 2 SH; in which the free thio groups of R 2 and R 4 form a disulfide bond; or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
31 words
A compound of claim 8, wherein R 12 is substituted or unsubstituted aryl, or substituted or unsubstituted aryl lower alkyl, and R 18 is H; or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
50 words
A compound of claim 9, wherein R 1 is NH 2 ; R 3 is CH 2 ; R 5 is C(O); R 9 is H; and R 12 is substituted or unsubstituted phenyl or benzyl, where said substituent is lower alkyl or halo; or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
11 words
A compound of claim 1, said compound of the formula ##STR5##
Claim 13
Dependent Claim
33 words
A method of treating tumors or restenosis in a subject in need of said treatment, which comprises administering to said subject a therapeutically effective amount of the compound or salt of claim 1.
Claim 14
Dependent Claim
35 words
A method of treating tumors or restenosis in a subject in need of said treatment, which comprises administering to said subject a therapeutically effective amount of a compound or salt thereof according to claim 11.
Claim 15
Dependent Claim
13 words
A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically-acceptable carrier.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-06-15 | 2001-12-15 | 2002-06-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-06-15 | 2005-12-15 | 2006-06-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-06-15 | 2009-12-15 | 2010-06-16 | $7700.00 | Window Closed / Lapsed |